RxDoctor Payments Data

Owaise Mansuri, MD

Internal Medicine · Champaign, ILNPI 1124280409

Payments from drug & device makers

$549in general payments, 2019–2025

Across 18 payments — averaging $30.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$106
  • Amgen$92
  • Sanofi$72
  • Insulet Corporation$46
  • Sequel Med Tech, LLC$44
  • Sanofi-aventis U.S. LLC$33
  • plus $155 from 7 others

What the payments were for

  • Speaking & faculty fees$7213%
  • Food & beverage$46384%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$549 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$593,839
Medicare patients
703
Services billed
8,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide459$609,518
JardianceEmpagliflozin461$521,370
MounjaroTirzepatide346$394,401
TrulicityDulaglutide191$218,835
Humulin R U-500 KwikpenInsulin Regular, Human95$184,188
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7147$154,644
RybelsusSemaglutide80$117,039
JanuviaSitagliptin Phosphate87$98,406
FarxigaDapagliflozin Propanediol97$91,568
Humalog Kwikpen U-200Insulin Lispro37$89,459
Fiasp FlextouchInsulin Aspart (Niacinamide)58$64,763
Tresiba Flextouch U-200Insulin Degludec55$64,131
Novolog FlexpenInsulin Aspart217$64,069
Humalog Kwikpen U-100Insulin Lispro168$61,814
Tresiba Flextouch U-100Insulin Degludec71$57,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCLantus, Admelog$33$32,969137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →